Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,041 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,668 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 38 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06215950 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jan 22, 2024 |
| NCT06193993 | Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients | active not recruiting | Phase 1 | 10 | National University Hospital, SingaporeOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT03319628 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | active not recruiting | Phase 1 / Phase 2 | 523 | Mersana TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06010875 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05210270 | HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy(HYACINCT) | not yet recruiting | Phase 1 / Phase 2 | 55 | University of Santo Tomas Hospital, PhilippinesOTHER | 0 | Jan 31, 2023 | clinicaltrials |
| NCT05366478 | A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT03444844 | Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Five Eleven Pharma, Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT05172310 | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | recruiting | Phase 1 | 410 | Karolinska University HospitalOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT03294889 | ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer | recruiting | Phase 1 / Phase 2 | 45 | University Hospital, GenevaOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT01913106 | HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer | recruiting | Phase 1 / Phase 2 | 25 | The Methodist Hospital Research InstituteOTHER | 1 | Jul 1, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jan 26, 2024source: clinicaltrials